Immunovant, Inc. Expected to Post FY2027 Earnings of ($1.84) Per Share (NASDAQ:IMVT)

Immunovant, Inc. (NASDAQ:IMVT) – Investment analysts at Zacks Research issued their FY2027 EPS estimates for shares of Immunovant in a report issued on Monday, June 17th. Zacks Research analyst E. Bagri anticipates that the company will earn ($1.84) per share for the year. The consensus estimate for Immunovant’s current full-year earnings is ($2.10) per share.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Wednesday, May 29th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). During the same period in the previous year, the business earned ($0.46) EPS.

IMVT has been the subject of a number of other research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunovant in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $51.00 target price on shares of Immunovant in a research report on Thursday, May 30th. Truist Financial reissued a “buy” rating and set a $48.00 target price on shares of Immunovant in a research report on Monday, March 25th. The Goldman Sachs Group assumed coverage on shares of Immunovant in a research report on Wednesday, March 13th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, Oppenheimer lowered their price objective on shares of Immunovant from $50.00 to $46.00 and set an “outperform” rating for the company in a research report on Monday, June 3rd. Seventeen analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunovant has a consensus rating of “Buy” and an average price target of $48.75.

Immunovant Stock Performance

IMVT opened at $26.19 on Wednesday. The firm has a 50 day moving average price of $28.22 and a 200 day moving average price of $34.01. The company has a market cap of $3.83 billion, a PE ratio of -13.78 and a beta of 0.67. Immunovant has a 1 year low of $18.16 and a 1 year high of $45.58.

Insider Transactions at Immunovant

In related news, CEO Peter Salzmann sold 4,807 shares of the firm’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $31.18, for a total transaction of $149,882.26. Following the transaction, the chief executive officer now directly owns 1,086,958 shares in the company, valued at $33,891,350.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Peter Salzmann sold 4,807 shares of the firm’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $31.18, for a total transaction of $149,882.26. Following the transaction, the chief executive officer now directly owns 1,086,958 shares in the company, valued at $33,891,350.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Eva Renee Barnett sold 12,253 shares of the firm’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $29.06, for a total value of $356,072.18. Following the transaction, the chief financial officer now owns 359,456 shares in the company, valued at $10,445,791.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 99,948 shares of company stock valued at $2,936,889. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Immunovant

Hedge funds have recently added to or reduced their stakes in the stock. Headlands Technologies LLC bought a new stake in Immunovant in the fourth quarter valued at $27,000. Assetmark Inc. bought a new stake in shares of Immunovant during the fourth quarter valued at about $61,000. EntryPoint Capital LLC raised its stake in shares of Immunovant by 288.8% during the first quarter. EntryPoint Capital LLC now owns 2,912 shares of the company’s stock valued at $94,000 after purchasing an additional 2,163 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Immunovant during the fourth quarter valued at about $212,000. Finally, CoreCap Advisors LLC raised its stake in shares of Immunovant by 11.2% during the fourth quarter. CoreCap Advisors LLC now owns 6,407 shares of the company’s stock valued at $270,000 after purchasing an additional 647 shares in the last quarter. 47.08% of the stock is currently owned by institutional investors.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.